Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1
|
|
|
- Maude Bailey
- 10 years ago
- Views:
Transcription
1 9/8/2015 Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 Stefan Eichmüller, PhD GMP & T Cell Therapy Unit, German Cancer Research Center, Heidelberg, Germany
2 Introduction Aim: Licensing patient s immune system to defend cancer Include different immune cells (CD8, CD4 T cells), inhibitory and stimulatory molecules T-helper-1-cell cytokines drive cancer into senescence Braumüller et al., Nature 2013 CD4+ T cells predict breast cancer survival Gu-Trantien et al., J Clin. Invest Antigen-specific CD4 + T cells in breast cancer Target antigen: NY-BR-1
3 NY-BR-1 is expressed in breast cancer cells 1. NY-BR-1 mrna expression breast tissue, prostate, testis overexpressed in 80% of all tested breast cancers Jäger, Cancer Res Mar 1;61(5): NY-BR-1 protein expression solely in epithelial cells of the breast 60% of invasive ductal mammary carcinomas NY-BR-1
4 T cell epitope restriction MHC-I MHC-II CD8 + T cells: =>Direct targeting of MHC-I + tumor cells CD4 + T cells: => targeting of tumor cells (1) Licensing of DCs to effectively prime CTLs (2) Direct stimulation of CTLs (3) Tumor stroma targeting (TAMs) NY-BR-1 class I epitopes: Jäger et al., 2005, Wang et al., 2006 NY-BR-1 class II epitopes: Gardyan et al., 2015
5 Screening of a NY-BR-1-specific library leads to the identification of NY-BR-1 candidate epitopes 1. Screening of a NY-BR-1-specific peptide library library peptide predicted epitope library peptide predicted epitope 2. In silico analysis of predicted NY-BR-1 specific candidate epitopes (SYFPEITHI database) (20mer) (15mer) prediction score (*) (HLA-DRB1*0301) (20mer) (15mer) prediction score (*) (HLA-DRB1*0401) #12 BR #156 BR #169 BR #68 BR #97/82 BR1-656/ #156 BR *SYFPEITHI database
6 Detection of epitope specific T cell-response in HLA-tg mice vaccinated with a NY-BR-1 encoding expression vector A: DR3tg mice B: DR4tg mice immunization: DNA read-out: 15 mer peptides (putative epitopes) detection of epitope
7 Confirmation of HLA-DR-restriction of murine NY-BR-1-specific CD4 + T cell lines A: T cell lines form DR3tg mice B: T cell lines from DR4tg mice T2: human, class II negative tumor cell line (TxB) transfectants express DR4 or DR3 HLA restriction
8 NY-BR-1-specific CD4 + T cell epitopes are processed by human cells A: DR3tg B: DR4tg Ad.NY-BR-1 Ad. untreated Ad.NY-BR-1 Ad. untreated ctrl. pep. spec. pep. ctrl. pep. spec. pep. Ad.NY-BR-1 Ad. untreated Ad.NY-BR-1 Ad. untreated ctrl. pep. spec. pep. ctrl. pep. spec. pep IFNγ spots / 1x10 5 CD4 + T cells IFNγ spots / 1x10 5 CD4 + T cells * over-saturated wells natural processing in human cells
9 Patients characteristics (selected for NY-BR-1 expression and HLA type) Patient code BC#1 BC#2 BC#3 BC#4 BC#5 BC#6 BC#7 Age at first diagnosis Primary tumor no yes yes yes yes yes yes Metastasis Lung, liver no no no no no no TNM T2 N0 M1 T2 N3 M0 T1 N1 M0 T2 N2 M0 T2 N1 M0 T4 N0 M0 T2 N1 M0 ER (2) 4/12 8/8 8/8 8/8 8/8 8/8 8/8 PgR (2) 12/12 7/8 8/8 8/8 8/8 8/8 8/8 Her2/neu Phenotype ILC Luminal-B Luminal-A Luminal-B Luminal-A Luminal-B Luminal-A HLA-DRB1* Chemotherapy before blood draw Irradiation before blood draw Vinorelbin no n.a. no no no no 11 years no no no no no no Biopsy before blood draw NY-BR-1 intensity (3) NY-BR-1 + cells (frequency) 80% 50% 90% 70% 90% 40% 90%
10 NY-BR-1 expression in tumors from breast cancer patients (BC) selected for HLA-type BC#1 BC#2 BC#4 BC#5 BC#7
11 NY-BR-1-specific CD4 + T cells are among PBMCs obtained from breast cancer patients (BC) m: medium p: specific peptide patients have specific T cells
12 Summary 1. Identification of NY-BR-1-specific, HLA-restricted CD4 + T cell epitopes 2. Establishment of murine HLA-restricted CD4 + T cell lines 3. Confirmation of endogenous processing of the newly identified epitopes in human cells 4. Detection of NY-BR-1-specific CD4 + T cells among PBMCs of breast cancer patients
13 Outlook 1. Detection of NY-BR-1-specific CD4 + T cells among PBMCs of breast cancer patients (ex vivo), using NY-BR-1-specific, HLA-DRB1*0301-/HLA-DRB1*0401-restricted MHC-II tetramers => Immunomonitoring of specific CD4+ cells 2. Sequencing and cloning of a NY-BR-1-specific TCR => Usage of epitopes as helper peptides for vaccine development
14 DKFZ (Heidelberg) Prof. Stefan Eichmüller Dr. Wolfram Osen Dr. Adriane Gardyan Krishna Das Elke Dickes Thank you for your attention! Cooperations Prof. Dr. Schneeweiss (Gynecology and Obstetrics, University Hospital Heidelberg) PD Dr. Sebastian Aulmann (Pathology, University Hospital Heidelberg) Prof. Dirk Jäger (National Center of Tumor Diseases, Heidelberg)
15 Backup
16 HLA-transgenic mouse models DR3tg mice DR4tg mice genotype MHC-I MHC-II mouse K b /D b HLA-DRB1*0301/ IA b-/- mouse K b /D b HLA-DRB1*0401/ IA b-/-
17 Screening of a NY-BR-1-specific library leads to the identification of NY-BR-1 candidate epitopes 1. Screening of a NY-BR-1-specific peptide library
18 NY-BR-1 peptide library (combinatorial analysis) K1 K2 K3 K4 K5 K6 K7 K8 K9 K10 K11 K12 K13 L L L L L L L L L L L L L Epitope containing library peptides recognized by spleen cells of DR3tg mice or DR4tg mice, respectively.
19 NY-BR-1 peptide library (combinatorial analysis) K1 K2 K3 K4 K5 K6 K7 K8 K9 K10 K11 K12 K13 L L L L L L L L L L L L L Epitope containing library peptides recognized by spleen cells of DR3tg mice or DR4tg mice, respectively.
20 NY-BR-1 peptide library (combinatorial analysis) K1 K2 K3 K4 K5 K6 K7 K8 K9 K10 K11 K12 K13 L L L L L L L L L L L L L Epitope containing library peptides recognized by spleen cells of DR3tg mice or DR4tg mice, respectively.
21 Screening of a NY-BR-1-specific library leads to the identification of NY-BR-1 candidate epitopes 1. Screening of a NY-BR-1-specific peptide library library peptide (20mer) predicted epitope (15mer) prediction score (*) (HLA-DRB1*0301) library peptide (20mer) predicted epitope (15mer) prediction score (*) (HLA-DRB1*0401) #12 BR #156 BR #169 BR #68 BR #97/82 BR1-656/ #156 BR *SYFPEITHI database
Activation and effector functions of HMI
Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
BioMmune Technologies Inc. Corporate Presentation 2015
BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical
A disease and antibody biology approach to antibody drug discovery
A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!
T cell Epitope Prediction
Institute for Immunology and Informatics T cell Epitope Prediction EpiMatrix Eric Gustafson January 6, 2011 Overview Gathering raw data Popular sources Data Management Conservation Analysis Multiple Alignments
B Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
Recognition of T cell epitopes (Abbas Chapter 6)
Recognition of T cell epitopes (Abbas Chapter 6) Functions of different APCs (Abbas Chapter 6)!!! Directon Routes of antigen entry (Abbas Chapter 6) Flow of Information Barrier APCs LNs Sequence of Events
specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
Mesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam
Mesothelioma 2014 Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Disclosures Grants from Pfizer and Roche Advisor for MSD and Verastem Once upon a time. http://amlbenzene.net/diseases-asbestos.htm
Cancer: DNA Synthesis, Mitosis, and Meiosis
Chapter 5 Cancer: DNA Synthesis, Mitosis, and Meiosis Copyright 2007 Pearson Copyright Prentice Hall, 2007 Inc. Pearson Prentice Hall, Inc. 1 What Is Cancer? Benign tumors do not invade surrounding tissue
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
Custom Antibody Services
Custom Antibody Services Custom service offerings DNA sequence Plasmid Peptide Structure Protein Peptide Small molecule Cells Spleen Lymphocytes Antigen Preparation Immunization Fusion & Subcloning Expansion
Immunovaccine Inc. (TSX-V: IMV)
May 2014 Immunovaccine Inc. (TSX-V: IMV) Targeted T cell Activation Immunotherapies FORWARD-LOOKING STATEMENTS This document contains forward-looking information pursuant to applicable securities law.
Immuno-Oncology Therapies to Treat Lung Cancer
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
T Cell Immunotherapy for Cancer
T Cell Immunotherapy for Cancer Chimeric Antigen Receptors Targeting Tag-72 Glycoprotein for Colorectal Cancer Mitchell H. Finer Ph.D Genetix Pharmaceuticals Inc Work Completed at Cell Genesys Inc T Cell
Modelling and analysis of T-cell epitope screening data.
Modelling and analysis of T-cell epitope screening data. Tim Beißbarth 2, Jason A. Tye-Din 1, Gordon K. Smyth 1, Robert P. Anderson 1 and Terence P. Speed 1 1 WEHI, 1G Royal Parade, Parkville, VIC 3050,
CONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294
AD Award Number: W81XWH-08-1-0030 TITLE: Regulation of Prostate Cancer Bone Metastasis by DKK1 PRINCIPAL INVESTIGATOR: Gregory A. Clines, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Alabama at
Detection of T-cell T and their application to vaccine design
QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture Detection of T-cell T epitopes and their application to vaccine design EpiVax Inc. 16 Bassett Street Providence Rhode Island
Superior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes
Superior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes Outlines Brief introduction of OriGene s mission on gene-centric product solution. TrueMAB monoclonal antibody
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression
Analysis of the adaptive immune response to West Nile virus
Analysis of the adaptive immune response to West Nile virus Jonathan Bramson (PI) Robin Parsons Alina Lelic Galina Denisova Lesley Latham Carole Evelegh Dmitri Denisov Strategy for characterizing T cell
Gene Silencing Oligos (GSOs) Third Generation Antisense
Gene Silencing Oligos (GSOs) Third Generation Antisense Walter R. Strapps, Ph.D. Executive Director, RNA Therapeutics Idera Pharmaceuticals Cambridge, MA NASDAQ: IDRA www.iderapharma.com Idera is a leader
WntResearch. Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer
WntResearch Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer Why WntResearch is developing novel anti-cancer drugs Approximately 55 000 Swedish citizens are diagnosed with cancer every
T Cell Maturation,Activation and Differentiation
T Cell Maturation,Activation and Differentiation Positive Selection- In thymus, permits survival of only those T cells whose TCRs recognize self- MHC molecules (self-mhc restriction) Negative Selection-
Breast Cancer. The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer.
Breast Cancer What Does the Pathology Report Say Normal Cells The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer. Non-Invasive
The Costimulatory Molecule CD27 Maintains Clonally
Immunity, Volume 35 Supplemental Information The Costimulatory Molecule CD7 Maintains Clonally Diverse CD8 + T Cell Responses of Low Antigen Affinity to Protect against Viral Variants Klaas P.J.M. van
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic
Dendritic Cells: A Basic Review *last updated May 2003
*last updated May 2003 Prepared by: Eric Wieder, PhD MD Anderson Cancer Center Houston, TX USA What is a dendritic cell? Dendritic cells are antigen-presenting cells (APCs) which play a critical role in
Wissenschaftliche Highlights der GSF 2007
H Forschungszentrum für Umwelt und Gesundheit GmbH in der Helmholtzgemeinschaft Wissenschaftlich-Technische Abteilung Wissenschaftliche Highlights der GSF 2007 Abfrage April 2007 Institut / Selbst. Abteilung
Immune Therapy for Pancreatic Cancer
Immune Therapy for Pancreatic Cancer December 16, 2014 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only:
ΔΕΝΤΡΙΤΙΚΑ ΚΥΤΤΑΡΑ ΚΑΙ ΕΜΒΟΛΙΑ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ DENDRITIC CELLS AND CANCER VACCINES
ΔΕΝΤΡΙΤΙΚΑ ΚΥΤΤΑΡΑ ΚΑΙ ΕΜΒΟΛΙΑ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ DENDRITIC CELLS AND CANCER VACCINES David Hunt. Cell Systems Initiative, U. of Washington. Βαίος Καρανίκας EU Marie Curie Fellow Μοναδα Ανοσολογίας Καρκίνου
www.downstatesurgery.org
Male Breast Cancer Rabih Nemr MD Kings County Hospital August 2008 ACGME Core Competencies 1 Patient t Care Medical Knowledge 2 g 3 4 Practice Based Learning/Improvement Interpersonal Communication Skills
Making the switch to a safer CAR-T cell therapy
Making the switch to a safer CAR-T cell therapy HaemaLogiX 2015 Technical Journal Club May 24 th 2016 Christina Müller - chimeric antigen receptor = CAR - CAR T cells are generated by lentiviral transduction
Update on Clinical Trials and Foundation Funded Grants
Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control
Breast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.
Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast
Chimeric Antigen Receptor T Cell Therapy
Chimeric Antigen Receptor T Cell Therapy Yi Lin, MD, PhD Mayo Clinic, Rochester, MN Alliance Spring Group Meeting - May 13, 2016 Presentation Objectives l Scientific overview of chimeric antigen receptor
Robert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
New strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
Developments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD [email protected] Contents Introduction Lung cancer pathogenesis NSCLC treatment options
PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition [email protected] September 23, 2010 Screening: 3 tests for PCa A good screening
Immunotherapy of Uveal Melanoma
Eye Am Not Alone (EANA) Patient Retreat Saturday Session - March 3, 2012 Immunotherapy of Uveal Melanoma Do not distribute or copy without the express permission of the Ocular Melanoma Foundation (OMF).
TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS
TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS Karine Lélu 1, Alexei Evlachev 1, Roland Kratzer 1, Sarah
Newsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:
Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
OBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
Immunologic approaches to breast cancer treatment
Surg Oncol Clin N Am 14 (2005) 1 31 Immunologic approaches to breast cancer treatment Michael S. Sabel, MD*, Matthew A. Nehs Department of Surgery, University of Michigan, 3304 Cancer Center, 1500 East
Bottle-neck Problems of Current Human Cancer Therapy
International Conference on Human Cell, Tissue-based Products and Tissue Banks, Oct. 13-14,Taipei, Taiwan Autologous Dendritic Cell-based Immunotherapy of Glioblastoma Multiforme: Post-Phase-I Clinical
WP3 Evaluation and development of technologies for predicting immunogenicity
WP3 Evaluation and development of technologies for predicting immunogenicity Co-leaders Bernard Maillere, CEA Sebastian Spindeldreher, Novartis Pharma Christian Pedersen Ross, Novonordisk Objectives of
Genetics of Rheumatoid Arthritis Markey Lecture Series
Genetics of Rheumatoid Arthritis Markey Lecture Series Al Kim [email protected] 2012.09.06 Overview of Rheumatoid Arthritis Rheumatoid Arthritis (RA) Autoimmune disease primarily targeting the synovium
Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
Anti-HER2 vaccines: new prospects for breast cancer therapy Maha Zohra Ladjemi 1, William Jacot 2, Thierry Chardès
Anti-HER2 vaccines: new prospects for breast cancer therapy Maha Zohra Ladjemi 1, William Jacot 2, Thierry Chardès 1 1, Andr é Pèlegrin, Isabelle Navarro-Teulon 1 * 1 IRCM, Institut de recherche en cancérologie
Potency Assays for an Autologous Active Immunotherapy (Sipuleucel-T) Pocheng Liu, Ph.D. Senior Scientist of Product Development Dendreon Corporation
Potency Assays for an Autologous Active Immunotherapy (Sipuleucel-T) Pocheng Liu, Ph.D. Senior Scientist of Product Development Dendreon Corporation Sipuleucel-T Manufacturing Process Day 1 Leukapheresis
Geniron. Custom Antibody Services. Serum services Antibody Monoclonal. Purification Antibody Mono Y Genetic Immunization Genbody Polyclonal Antibody
Geniron Custom Antibody Services Serum services Antibody Monoclonal Purification Antibody Mono Y Genetic Immunization Genbody Polyclonal Antibody Geniron Poly Y WE PROVIDE OUR SERVICES TO With Expertise
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
Targeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
Immunovaccine Inc. (TSX-V: IMV) July 2011
Immunovaccine Inc. (TSX-V: IMV) July 2011 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
Receptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?
Receptor conversion in distant breast cancer metastases Breast cancer metastases: A spitting image of their primary? Introduction Breast cancer is the leading cause of female cancer death worldwide (13,000
A Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer
Proportion of patients with invasive breast cancer in whom ER, PR and/or
1.1.a. Proportion of patients with invasive breast cancer in whom ER, PR and/or HER2 status assessment were performed 1.1.b. Proportion of patients with invasive breast cancer in whom systemic treatment
A new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; [email protected] (2) Steven
Non-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
Breast cancer and normal cell lines
The Essentials of Life Science Research Globally Delivered Breast cancer and normal cell lines ATCC No. Name Tissue Cell Type Disease Oganism Age Ethnicity Genes Expressed CRL-7227 Hs 281.T CRL-7245 Hs
Final Review. Aptamers. Making Aptamers: SELEX 6/3/2011. sirna and mirna. Central Dogma. RNAi: A translation regulation mechanism.
Central Dogma Final Review Section Week 10 DNA RNA Protein DNA DNA replication DNA RNA transcription RNA Protein translation **RNA DNA reverse transcription http://bass.bio.uci.edu/~hudel/bs99a/lecture20/lecture1_1.html
Future Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France Bone metastases 70 % of prostate and breast cancers 30 % of lung, bladder and thyroid
Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too.
Male Breast Cancer Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too. Many people do not know that men can get breast
Oncology Medical Home Measure Specification Data
Oncology Medical Home Measure Specification Data Measure Name Chemotherapy pathway compliance Measure # 1 Measure Description % of chemotherapy treatments that have adhered to NCCN guidelines or pathways.
Microbiology AN INTRODUCTION EIGHTH EDITION
TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein
Oncology. Objectives. Cancer Nomenclature. Cancer is a disease of the cell Cancer develops when certain cells begin to grow out of control
Oncology Objectives Describe the etiology and pathophysiological mechanisms of cancer Discuss medical and family history findings relevant to cancer Identify general signs and symptoms associated with
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000
A Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
FGF-1 as Cosmetic Supplement
FGF-1 as Cosmetic Supplement Ing-Ming Chiu, Ph.D. Professor, Internal Medicine and Molecular and Cellular Biochemistry The Ohio State University Columbus, Ohio, U.S.A. GENTEON USA Fibroblast Growth Factor
The Immune System: A Tutorial
The Immune System: A Tutorial Modeling and Simulation of Biological Systems 21-366B Shlomo Ta asan Images taken from http://rex.nci.nih.gov/behindthenews/uis/uisframe.htm http://copewithcytokines.de/ The
Enhancing Anti-Tumor Activity of Checkpoint Inhibition
Enhancing Anti-Tumor Activity of Checkpoint Inhibition Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Laboratory of Tumor
Types of Cancers [-oma growth ]!
Cancer: disease of transcription factors and replication 1 Uncontrolled cell growth and division -> immortalized cells -> tumor growth -> metastasis (cells float away from tumor and spread throughout the
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
.org. Metastatic Bone Disease. Description
Metastatic Bone Disease Page ( 1 ) Cancer that begins in an organ, such as the lungs, breast, or prostate, and then spreads to bone is called metastatic bone disease (MBD). More than 1.2 million new cancer
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers. SMi 4 th Annual Cancer Vaccines Conference September 16, 2015
DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers SMi 4 th Annual Cancer Vaccines Conference September 16, 2015 Disclaimer Certain statements made in this presentation are forward-looking
Patient Guide to Breast Cancer Surgery and Treatment
Patient Guide to Breast Cancer Surgery and Treatment Coree H. Flight attendant and mother of 3. Diagnosed with invasive breast cancer in 2009. An educational guide prepared by Genomic Health This Is Your
HER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
